Literature DB >> 28280261

Non-kinase targets of protein kinase inhibitors.

Lenka Munoz1.   

Abstract

Kinome-wide profiling platforms have comprehensively identified the relevant kinases that are targeted by numerous protein kinase inhibitors. However, recent projects have begun to discover non-kinase targets of kinase inhibitors. These non-kinase targets can contribute to the desired or undesired activities of inhibitors, or act as silent bystanders. As a full awareness of a drug's mechanism of action is crucial for the interpretation of results and for successful preclinical and clinical drug development, these discoveries highlight the importance of understanding the pharmacology of kinase inhibitors beyond the kinome. In this Review, I discuss kinase inhibitors for which non-kinase targets have been identified and the application of emerging techniques to validate drug-target engagement in intact cells.

Mesh:

Substances:

Year:  2017        PMID: 28280261     DOI: 10.1038/nrd.2016.266

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  162 in total

1.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Authors:  A Pardanani; J Hood; T Lasho; R L Levine; M B Martin; G Noronha; C Finke; C C Mak; R Mesa; H Zhu; R Soll; D G Gilliland; A Tefferi
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

2.  Methyl 3-((6-methoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)amino)benzoate (GN39482) as a tubulin polymerization inhibitor identified by MorphoBase and ChemProteoBase profiling methods.

Authors:  Hidemitsu Minegishi; Yushi Futamura; Shinji Fukashiro; Makoto Muroi; Makoto Kawatani; Hiroyuki Osada; Hiroyuki Nakamura
Journal:  J Med Chem       Date:  2015-05-11       Impact factor: 7.446

3.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

4.  Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.

Authors:  Katrien Busschots; Laura A Lopez-Garcia; Carmen Lammi; Adriana Stroba; Stefan Zeuzem; Albrecht Piiper; Pedro M Alzari; Sonja Neimanis; Jose M Arencibia; Matthias Engel; Jörg O Schulze; Ricardo M Biondi
Journal:  Chem Biol       Date:  2012-09-21

5.  Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.

Authors:  Mathew P Martin; Sanne H Olesen; Gunda I Georg; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2013-09-10       Impact factor: 5.100

6.  RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis.

Authors:  Marius Dannappel; Katerina Vlantis; Snehlata Kumari; Apostolos Polykratis; Chun Kim; Laurens Wachsmuth; Christina Eftychi; Juan Lin; Teresa Corona; Nicole Hermance; Matija Zelic; Petra Kirsch; Marijana Basic; Andre Bleich; Michelle Kelliher; Manolis Pasparakis
Journal:  Nature       Date:  2014-08-17       Impact factor: 49.962

7.  Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Authors:  David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

8.  Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.

Authors:  Kim Newton; Debra L Dugger; Katherine E Wickliffe; Neeraj Kapoor; M Cristina de Almagro; Domagoj Vucic; Laszlo Komuves; Ronald E Ferrando; Dorothy M French; Joshua Webster; Merone Roose-Girma; Søren Warming; Vishva M Dixit
Journal:  Science       Date:  2014-02-20       Impact factor: 47.728

9.  The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Authors:  Gabriela Brumatti; Chunyan Ma; Najoua Lalaoui; Nhu-Y Nguyen; Mario Navarro; Maria C Tanzer; Jennifer Richmond; Margherita Ghisi; Jessica M Salmon; Natasha Silke; Giovanna Pomilio; Stefan P Glaser; Elisha de Valle; Raffi Gugasyan; Mark A Gurthridge; Stephen M Condon; Ricky W Johnstone; Richard Lock; Guy Salvesen; Andrew Wei; David L Vaux; Paul G Ekert; John Silke
Journal:  Sci Transl Med       Date:  2016-05-18       Impact factor: 17.956

10.  Using transcriptome sequencing to identify mechanisms of drug action and resistance.

Authors:  Sarah A Wacker; Benjamin R Houghtaling; Olivier Elemento; Tarun M Kapoor
Journal:  Nat Chem Biol       Date:  2012-02-12       Impact factor: 15.040

View more
  34 in total

1.  SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).

Authors:  Christopher R M Asquith; Benedict-Tilman Berger; Jing Wan; James M Bennett; Stephen J Capuzzi; Daniel J Crona; David H Drewry; Michael P East; Jonathan M Elkins; Oleg Fedorov; Paulo H Godoi; Debra M Hunter; Stefan Knapp; Susanne Müller; Chad D Torrice; Carrow I Wells; H Shelton Earp; Timothy M Willson; William J Zuercher
Journal:  J Med Chem       Date:  2019-02-26       Impact factor: 7.446

Review 2.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

3.  Determination of protein kinase A activity and inhibition by using hydroxyapatite nanoparticles as a fluorescent probe.

Authors:  Kaina Zhang; Ke Zeng; Congcong Shen; Shiyu Tian; Minghui Yang
Journal:  Mikrochim Acta       Date:  2018-03-16       Impact factor: 5.833

4.  A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.

Authors:  Suman Rao; Guangyan Du; Marc Hafner; Kartik Subramanian; Peter K Sorger; Nathanael S Gray
Journal:  J Biol Chem       Date:  2019-03-11       Impact factor: 5.157

5.  Synergism between the Synthetic Antibacterial and Antibiofilm Peptide (SAAP)-148 and Halicin.

Authors:  Miriam E van Gent; Tanny J K van der Reijden; Patrick R Lennard; Adriëtte W de Visser; Bep Schonkeren-Ravensbergen; Natasja Dolezal; Robert A Cordfunke; Jan Wouter Drijfhout; Peter H Nibbering
Journal:  Antibiotics (Basel)       Date:  2022-05-17

6.  Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TüKIC Library.

Authors:  Enni-Kaisa Mustonen; Tatu Pantsar; Azam Rashidian; Juliander Reiner; Matthias Schwab; Stefan Laufer; Oliver Burk
Journal:  Cells       Date:  2022-04-12       Impact factor: 7.666

7.  Dopamine-Dependent QR2 Pathway Activation in CA1 Interneurons Enhances Novel Memory Formation.

Authors:  Nathaniel L Gould; Vijendra Sharma; Mohammad Hleihil; Sailendrakumar Kolatt Chandran; Orit David; Efrat Edry; Kobi Rosenblum
Journal:  J Neurosci       Date:  2020-10-12       Impact factor: 6.167

8.  Conflicting evidence for the role of JNK as a target in breast cancer cell proliferation: Comparisons between pharmacological inhibition and selective shRNA knockdown approaches.

Authors:  Rachel A Wood; Mark J Barbour; Gwyn W Gould; Margaret R Cunningham; Robin J Plevin
Journal:  Pharmacol Res Perspect       Date:  2018-02

Review 9.  Drug repurposing: progress, challenges and recommendations.

Authors:  Sudeep Pushpakom; Francesco Iorio; Patrick A Eyers; K Jane Escott; Shirley Hopper; Andrew Wells; Andrew Doig; Tim Guilliams; Joanna Latimer; Christine McNamee; Alan Norris; Philippe Sanseau; David Cavalla; Munir Pirmohamed
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 10.  Molecular targets and anticancer activity of quinoline-chalcone hybrids: literature review.

Authors:  Mamdouh F A Mohamed; Gamal El-Din A Abuo-Rahma
Journal:  RSC Adv       Date:  2020-08-21       Impact factor: 4.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.